In the treatment-naïve setting, there’s hardly any difference in treatment duration between the two phase-3 programs. The Boceprevir trial will have 28-week and 48-week active arms (#msg-29474929) while the Telaprevir trial*s* will have 24-week and 48-week active arms (#msg-26228377).
Moreover, in both phase-3 programs, only the patients who achieve an RVR and EVR will receive the short duration of therapy; in both programs, patients who fail to achieve an RVR or an EVR will get 48 weeks of treatment (if they continue at all).
Let’s talk biotech! “The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Market Data 
Markets 
AI
